EAU 2008 - Advances in Targeted Therapy and Tissue Engineering in Urology: Targeted Therapy
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - When a patient comes to the pharmacist in the future he may state: “Here is my sequence”. This could be a consequence of the development of targeted therapies as presented by Chris Evans. He pointed out that molecular profile of a patient will have an increasing impact on the selection patients for a diagnostic procedure or even a specific therapy.
Login to read more...
|
EAU 2008 - Prognostic Factors in Patients with Intermediate and High Risk Stage Ta T1 Papillary Carcinoma of the Bladder Treated with Maintenance Epirubicin or Maintenance Bacillus Calmette-Guerin
Friday, 04 April 2008
MILAN, ITALY (UroToday.com) - Results of EORTC GU Group study 30911
Login to read more...
|
EAU 2008 - Advances in Targeted Therapy and Tissue Engineering in Urology
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Evans (Sacramento) presented a lecture on targeted therapies. Most drugs have a mechanistic “target”, such as the enzymes 5-α reductase in the treatment of BPH or 5-phosphodiesterase in the treatment of erectile dysfunction. However, in the current presentation, “targeted therapy” is defined as molecular targeting.
Login to read more...
|
EAU 2008 - A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Results Only in Less Small-Sized (up to 0.5 cm) Recurrences
Friday, 04 April 2008
MILAN, ITALY (UroToday.com) - Dr. Holmang discussed whether a single instillation of epirubicin after transurethral resection (TUR) of bladder tumors would influence the interval to and size of the first recurrence.
Login to read more...
|
EAU 2008 - The Use of Biological Markers in Clinical Practice
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Bjartell (Lund) presented on the use of biological markers as they can apply to clinical practice. A useful biomarker, he said is a molecular test that provides additional information to clinical information.
Login to read more...
|
EAU 2008 - Nomograms for Prediction of Disease Recurrence and Progression in Patients with Newly Diagnosed Ta, T1Transitional Cell Carcinoma of the Bladder
Friday, 04 April 2008
MILAN, ITALY (UroToday.com) - Dr. Hong presented a newly developed and validated prognostic nomogram for disease recurrence and progression in patients with Ta and T1 transitional cell carcinomas (TCC) of the bladder.
Login to read more...
|
EAU 2008 - Management of Superficial Bladder Tumors: A Randomized Study Evaluating Maintenance Schedule in Early Adjuvant Chemotherapy For Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - An Italian study group presented data on the optimal schedule regimen and the role of maintenance intravesical chemotherapy or BCG immunotherapy after transurethral resection (TUR for non–muscle-invasive transitional cell cancer of the bladder (NMI TCCB) for patients at intermediate risk.
Login to read more...
|
EAU 2008 - Molecular Detection of Lymph Node Involvement in Genitourinary Cancer
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Michael Jewett (Toronto) presented the SIU lecture on detection and mapping regional lymph nodes (LN) in genitourinary cancer. He addressed the importance of LN in staging and therapy of GU cancers.
Login to read more...
|
EAU 2008 - Management of Superficial Bladder Tumors: Celecoxib for the Treatment of Non-Muscle Invasive Bladder Cancer
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - Cyclooxygenase-2 (Cox-2) expression increases with bladder cancer tumor grade and stage. Dr. Pagliarulo presented preliminary results from a clinical trial to evaluate the safety and efficacy of the selective inhibitor of Cox-2, celecoxib, in Ta and T1 bladder cancer patients
Login to read more...
|
EAU 2008 - Management of Superficial Bladder Tumors: Detrusor Muscle in the First Transurethral Resection of Bladder Tumor (TURBT) Specimen is a Surrogate Marker of Resection Quality and is Dependent on Operator Experience
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - This presentation addressed the issue that recurrence at first follow-up cystoscopy (RR-FFC) after TURBT has been attributed to incomplete resection of the tumor.
Login to read more...
|
EAU 2008 - Management of Superficial Bladder Tumors: Does Photo Dynamic TURB Improve Outcome of Initial T1 High Grade Bladder Cancer?
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - Long-term Follow-up of a
Randomized Study
Login to read more...
|
EAU 2008 - Management of Superficial Bladder Tumors: Group Study Comparing Epirubicin, Bacillus Calmette-Guerin (BCG), and BCG Plus Isoniazid
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacilus calmetteguerin (BCG), and BCG plus isoniazid in patients with
intermediate and high risk stage Ta T1 papillary carcinoma of the bladder
Login to read more...
|
EAU 2008 - Maintenance Bacillus Calmette-Guerin Immunotherapy for TaG3 or T1G3 and/or Carcinoma In Situ Transitional Cell Carcinoma of the Bladder
Wednesday, 02 April 2008
Login to read more...
|
EAU 2008 - Management of Superficial Bladder Tumors: Prediction of Recurrence and Progression of Non-muscle Invasive Bladder Cancer in Patients Treated with Bacillus Calmette-Guérin
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - A Scoring System Based on Multivariate Analysis of Data from Four Randomized CUETO Trials
Login to read more...
|
EAU 2008 - The Clinical Significance of Micro-Metastatic Lymph Node Disease in Kidney and Bladder Cancer
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Gschwend (Munich) presented a State-of-the-Art lecture on LN disease in renal and bladder cancers. He began with bladder cancer and that staging correlates with disease specific survival.
Login to read more...
|
Conference Coverage 
